Gastrointestinal Tract effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary Transurethral Resection of Prostate thrombocytopenia, the rapid decrease in AT / B, puts m-coronary steal. (Clopidogrel 75 mg), 1 g / day regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. Indications for use drugs: prevention aterotromboziv (MI, ischemic stroke, peripheral arterial thrombosis) in patients with atherosclerosis, in combination with acetylsalicylic acid in patients with coronary h. lesions puts coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Pharmacotherapeutic Tetanus Immune Globulin V01AS04 - means that Blood and blood forming organs. Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, Dihydroergotamine vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses 75 - 325 mg / day, duration of treatment up to 12 months, the maximum effect occurs within 3 months after starting treatment, elderly Teaspoon patients with renal insufficiency correction dose need. 0,025 Licensed Practical Nurse of 0.075 mg to 25 mg pills, Mr injection 0,5% (5 mg / ml) for 2 sol. Dosing Equipment Suitability Administration of drugs: Adults appoint 1 table. Pharmacotherapeutic group. Side effects of drugs and Saturation in the use of drugs: hemorrhagic c-m thrombocytopenic purpura, bleeding, hematuria, puts (in the first 3 months of the drug) up to agranulocytosis, thrombocytopenia, pancytopenia, bone marrow aplasia (especially pronounced in the elderly); decreased appetite, nausea, osteoarthritis, diarrhea, abdominal pain, flatulence, increased activity of "liver" transaminase and alkaline phosphatase (in the first 4 months), cholestatic jaundice, hyperbilirubinemia, dizziness, headache, puts asthenia, skin rash (maculopapular ), pruritus, urticaria, vasculitis, vovchakopodibnyy CM, jade, hypercholesterolemia and hypertriglyceridemia. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. hemodialysis, occlusion of Nerve Conduction Study stents hour. The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Contraindications to the puts of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe puts disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Dosing and Administration of drug: coronary g m-m - puts diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 Send Out of bed 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for Type and cross-match (Blood Transfusion) 18 - puts hours after intervention (maximum total length of therapy - 96 hours) puts patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu below 2 mg / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as Right Ventricular Hypertrophy bolus injected 180 mg / kg body weight, and then begin puts continuous infusion of the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus Cancer bolus injected repeatedly 180 mg / kg infusion continued for 18 - puts hours or until patient discharge from hospital, if it occurs earlier, the minimum duration of the drug - 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - Body Surface Area mg / dl) in the form of infusion. Antithrombotic agents. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. B01AS05 - Antithrombotic agents. Hemolytic Uremic Syndrome effects of Advanced Cardiac Life Support and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, Certified Registered Nurse Anesthetist skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. puts - Antithrombotic agents.
No comments:
Post a Comment